1887

Journal of General Virology header logo

Volume 75, Issue 8

Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera Free

Abstract

Recombinant human papillomavirus type 11 (HPV-11) virus-like particles (VLPs) were tested for their ability to induce the formation of neutralizing antibodies, and were also tested for serodiagnostic capabilities in an ELISA in comparison with HPV-11 whole virions. VLPs, purified by CsCl density gradient centrifugation from the cell-free supernatant of Ac 11 LI-infected Sf9 suspension cell cultures, were used to immunize rabbits and anti-VLP antibodies were tested in the athymic mouse model of HPV-11 infection. Pretreatment of infectious HPV-11 virions with the immune serum of VLP-treated animals caused a marked reduction of graft growth ( < 10) and viral gene expression ( < 10 ), similar to the effects obtained using whole virion postimmune serum, and consistent with immune neutralization. To assess the serodiagnostic capabilities of VLPs, a VLP ELISA was developed and used to analyse sera that were tested previously in an HPV-11 whole virion ELISA. Specific antibodies were detected in 49% of patients’ sera ( = 2 × 10), and individual VLP sero- reactivities correlated with those previously obtained using whole virions as the antigen (r = 0·87; < 10). These results indicate that recombinant VLPs can be used to elicit a neutralizing antibody response, and can substitute faithfully for native virions in the development of HPV-serodiagnostic immunoassays.

  • Received:
  • Accepted:
  • Published Online:
© The Journal of General Virology 1994
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-75-8-2075
1994-08-01
2024-04-16
Loading full text...

Full text loading...

/deliver/fulltext/jgv/75/8/JV0750082075.html?itemId=/content/journal/jgv/10.1099/0022-1317-75-8-2075&mimeType=html&fmt=ahah

References

  1. Bonnez W., Da Rin C., Rose R. C., Reichman R. C. 1991; Use of human papillomavirus type 11 virions in an ELISA to detect specific antibodies in humans with condylomata acuminata. Journal of General Virology 72:1343–1347
     [Google Scholar]
  2. Bonnez W., Kashima H. K., Leventhal B., Mounts P., Rose R. C., Reichman R. C., Shah K. V. 1992a; Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis. Virology 188:384–387
     [Google Scholar]
  3. Bonnez W., Rose R. C., Reichman R. C. 1992b; Antibody-mediated neutralization of human papillomavirus type 11 (HPV-11) infection in the nude mouse. Detection of HPV-11 mRNAs. Journal of Infectious Diseases 165:376–380
     [Google Scholar]
  4. Bonnez W., Da Rin C., Rose R. C., Tyring S. K., Reichman R. C. 1993; Evolution of the antibody response to human papillomavirus type 11 (HPV-11) in patients with condyloma acuminatum according to treatment response. Journal of Medical Virology 39:340–344
     [Google Scholar]
  5. Carter J. J., Hagensee M., Taflin M. C., Lee S. K., Koutsky L. A., Galloway D. A. 1993; HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts. Virology 195:456–462
     [Google Scholar]
  6. Christensen N. D., Kreider J. W. 1990; Antibody-mediated neutralization in vivo of infectious papillomavirus. Journal of Virology 64:3151–3156
     [Google Scholar]
  7. Christensen N. D., Kreider J. W., Shah K. V., Rando R. F. 1992; Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. Journal of General Virology 73:1261–1267
     [Google Scholar]
  8. Dimmock N. J. 1993 Neutralization of Animal Viruses Berlin: Springer-Verlag;
     [Google Scholar]
  9. Gross L. 1983 Oncogenic Viruses New York: Pergamon Press;
     [Google Scholar]
  10. Hagensee M. E., Yaegashi N., Galloway D. A. 1993; Selfassembly of human papillomavirus type 1 capsids by expression of the LI protein alone or by coexpression of the LI and L2 capsid proteins. Journal of Virology 67:315–322
     [Google Scholar]
  11. Kienzler J. L., Lemoine M. T., Orth G., Jibard N., Blanc D., Laurent R., Agache P. 1983; Humoral and cell-mediated immunity to human papillomavirus type 1 (HPV-1) in human warts. British Journal of Dermatology 108:665–672
     [Google Scholar]
  12. Kirnbauer R., Booy F., Cheng N., Lowy D. R., Schiller J. T. 1992; Papillomavirus LI major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proceedings of the National Academy of Sciences, U.S.A 89:12180–12184
     [Google Scholar]
  13. Kreider J. W., Howett M. K., Wolfe S. A., Bartlett G. L., Zaino R. J., Sedlacek T. V., Mortel R. 1985; Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata. Nature; London: 317639–641
     [Google Scholar]
  14. Kreider J. W., Howett M. K., Leure-Dupree A. E., Zaino R. J., Weber J. A. 1987; Laboratory production in vivo of infectious human papillomavirus type 11. Journal of Virology 61:590–593
     [Google Scholar]
  15. Kreider J. W., Patrick S. D., Cladel N. M., Welsh P. A. 1990; Experimental infection with human papillomavirus type 1 of human hand and foot skin. Virology 177:415–417
     [Google Scholar]
  16. Pfister H., Zur Hausen H. 1978; Seroepidemiological studies of human papilloma virus (HPV-1) infections. International Journal of Cancer 21:161–165
     [Google Scholar]
  17. Pfister H., Gross G., Hagedorn M. 1979; Characterization of human papillomavirus in warts of a renal allograft patient. Journal of Investigative Dermatology 73:349–353
     [Google Scholar]
  18. Reichman R. C., Bonnez W. 1990; Papillomaviruses. In Principles and Practice of Infectious Diseases pp. 1191–1200 Mandell G. L., Douglas R. G.Jr Bennett J. E. Edited by New York: Churchill Livingstone;
     [Google Scholar]
  19. Rose R. C., Bonnez W., Reichman R. C., Garcea R. L. 1993; Expression of human papillomavirus type 11 LI protein in insect cells: in vivo and in vitro assembly of viruslike particles. Journal of Virology 67:1936–1944
     [Google Scholar]
  20. Steele J. C., Gallimore P. H. 1990; Humoral assays of human sera to disrupted and nondisrupted epitopes of human papillomavirus type 1. Virology 174:388–398
     [Google Scholar]
  21. Tukey J. W. 1977 Exploratory Data Analysis Reading Massachusetts: Addison-Wesley;
     [Google Scholar]
  22. Viac J., Chomel J. -J., Chardonnet Y., Aymard M. 1990; Incidence of antibodies to human papillomavirus type 1 in patients with cutaneous and mucosal papillomas. Journal of Medical Virology 32:18–21
     [Google Scholar]
  23. Zhou J., Sun X. Y., Stenzel D. J., Frazer I. H. 1991; Expression of vaccinia recombinant HPV-16 LI and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virionlike particles. Virology 185:251–257
     [Google Scholar]
  24. Zur Hausen H. 1976; Condylomata acuminata and human genital cancer. Cancer Research 36:794
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-75-8-2075
Loading
Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera
J. Gen. Virol. 75, 2075 (1994); https://doi.org/10.1099/0022-1317-75-8-2075
/content/journal/jgv/10.1099/0022-1317-75-8-2075
/content/journal/jgv/10.1099/0022-1317-75-8-2075
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error